Carbapenem-Resistant Enterobacterales (CRE): A Focus on Ceftazidime-Avibactam and Meropenem-Vaborbactam

Antimicrobial resistance (AMR) has emerged as a leading global health threat with mortality rates due to infections from resistant organisms rising each year.¹ In the United States, the CDC estimates that nearly 3 million AMR infections occur annually, while AMR is responsible for more than 35,000 deaths.² Internationally, the WHO estimated that bacterial AMR was directly responsible for approximately 1.3 million deaths and contributed to nearly 5 million